logo

For the Inventor, By the Inventor

North Haven, CT, United States of America

Tai-Shun Lin

This inventor holds 17 USPTO granted patents. Top assignees: Yale University, Research, Incorporated, Research Foundation of State of N.y.. Active years: 1978-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tai-Shun Lin. Retrieved from https://idiyas.com/inventor/tai-shun-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 100.0

Average Co-Inventor Count = 2.2

ph-index = 7

Forward Citations = 122(Granted Patents)


Company Filing History:

goldMedal11 out of 1,368 
 
Yale University
 patents
silverMedal6 out of 444 
 
Research, Incorporated
 patents
bronzeMedal1 out of 3 
 
Research Foundation of State of N.y.
 patents
where one patent can have more than one assignee

Years Active: 1978-1999

Loading Chart...
17 patents (USPTO):Explore Patents
1. 6001818 - Use of 2',3'-dideoxycytidin-2'-ene (2'- (1999-12-14),
2. 5830881 - L-2'3',dideoxy nucleoside analogs as anti-hepatitus B (HBV) agents (1998-11-03),
3. 5721259 - Method of using 2-formylpyridine thiosemicarbazone compounds (1998-02-24),
4. 5631239 - L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents (1997-05-20),
5. 5627160 - L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and (1997-05-06),
6. 5561120 - Method for treating HBV infections with (1996-10-01),
7. 5281715 - 2-formylpyridine thiosemicarbazone compounds (1994-01-25),
8. 5192764 - Pyrazinone N-oxide nucleosides and analogs thereof (1993-03-09),
9. 5099010 - Intermediates in the preparation of 3'-amino-2',3'-dideoxycytidine and (1992-03-24),
10. 4978655 - Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in (1990-12-18),
11. 4806531 - 2,3-bis(aziridinyl)-1,4-naphthoquinone sulfonate derivatives having (1989-02-21),
12. 4710492 - 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients (1987-12-01),
13. 4604382 - 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable (1986-08-05),
14. 4600573 - Compositions and method for alleviating the toxic effects of (1986-07-15),
15. 4128639 - Nitrosourea analogs of thymidine (1978-12-05),

Title: The Innovative Journey of Tai-Shun Lin

Introduction: Tai-Shun Lin, a distinguished inventor hailing from North Haven, CT, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Tai-Shun Lin's latest patents include cutting-edge technologies in the realm of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a career spanning over two decades, Tai-Shun Lin has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing solutions that push the boundaries of what is possible. His innovative spirit has led to the creation of numerous patents that have revolutionized industries and improved the lives of many.

Collaborations: Throughout his career, Tai-Shun Lin has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects, highlighting his strong communication and leadership skills.

Conclusion: In conclusion, Tai-Shun Lin's passion for innovation, coupled with his dedication to creating impactful solutions, has solidified his position as a trailblazing inventor in the technology sector. His relentless pursuit of excellence and commitment to pushing the boundaries of what is possible continue to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…